The Efficacy of Second-Line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma with Bone Metastases: A Multi-Institutional Retrospective Study
crossref(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined